Compare Banco Santander SA (SAN) vs 10X Genomics Inc (TXG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Banco Santander SA vs 10X Genomics Inc — how do they compare? Banco Santander SA trades at $14.79 (market cap $218.36B), while 10X Genomics Inc trades at $67.59 (market cap $8.55B). The key difference: Banco Santander SA is far larger — about 25.5× 10X Genomics Inc's market cap, and Banco Santander SA pays a 1.87% dividend while 10X Genomics Inc pays none. Which is the better fit depends on your goals.
| SAN | TXG | |
|---|---|---|
Market Cap | $218.36B | $8.55B |
Sector | Financials | Health |
52-Week High | $15.05 | $67.29 |
52-Week Low | $9.65 | $11.34 |
Dividend Yield | 1.87% | — |
Enterprise Value | — | $8.08B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Banco Santander (SAN) trades at $14.86, down 0.47% on the day, with a bullish technical signal supported by moving averages. The stock shows a P/E of 14.47 and a net income margin of 26.25%, with Q1 2026 earnings beating expectations but Q2 missing. Recent news highlights the completion of the Webster acquisition, expanding U.S. presence and diversifying the banking franchise.
Outlook is positive with analyst consensus at 'Moderate Buy' (64% buy ratings), though risks include volatile cash flows and high debt levels. Revenue growth is steady, but negative operating cash flow in 2024-2025 warrants monitoring. The stock offers value with solid profitability, but investors should weigh acquisition integration risks against expansion benefits.
TXG trades at $65.60, up 4.71% today, with strong technical momentum showing bullish moving averages and key support at $63. Fundamentally, the company demonstrates improving trends with Q2 2026 earnings beating estimates and revenue growth guidance raised, though profitability remains negative with a -12.18% net margin. Recent patent victory against Parse Biosciences strengthens competitive positioning.
The outlook remains cautiously optimistic with analyst consensus at 45% buy ratings and $50.78 price target. Key opportunities include Atera platform adoption and consumables growth, while risks center on valuation premiums and ongoing profitability challenges. The stock trades near resistance at $67 with institutional interest showing mixed signals.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Banco Santander SA
Santander's focus is on retail and commercial banking. Latin America is geographically the largest operation, with Brazil by far the largest. Its continental European business is still mainly Iberian. Santander's U.K. presence is the result of the acquisition of building society Abbey. In the U.S., Santander operates a vehicle finance business and a regional bank focused on the Northeastern states.
Read more on SAN →About 10X Genomics Inc
10x Genomics Inc is a life science technology company based in the United States. Its solutions include instruments, consumables, and software for analyzing biological systems. The product portfolio of the company includes Chromium Controller, Reagent Kits, 10x Compatible Products, and Informatics Software among others. The majority of its revenue is generated from consumables.
Read more on TXG →
